SCHEMBL25464178

SCHEMBL25464178

CC(C)(C(=O)NC1CCC1)c1cccc(Cl)c1F

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.43
▸ TSHR P16473 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ RAB9A P51151 3/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ TAS1R3 Q7RTX0 2/20 0.40
▸ TAS1R1 Q7RTX1 2/20 0.40
▸ TAS1R2 Q8TE23 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ SSTR4 P31391 3/20 0.40
▸ HSD11B1 P28845 3/20 0.40
▸ SSTR1 P30872 2/20 0.40
▸ P2RX7 Q99572 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25464109 0.81 L3MBTL1 (0.44) EPHX2KDM4ETDP1RAB9ANPC1
SCHEMBL25464188 0.81 KMT2A (0.47) EPHX2SMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL25460825 0.79 PDK1 (0.42) KDM4ERAB9AKMT2AALDH1A1MEN1
SCHEMBL1626611 0.74 NOTUM (0.40) TSHRRAB9AKMT2AALDH1A1MEN1
SCHEMBL25464079 0.73 GRM5 (0.50) EPHX2SMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL1626668 0.73 PLCG1 (0.44) SMN1; SMN2RAB9AKMT2AMEN1
SCHEMBL25464076 0.71 MAPT (0.46) EPHX2SMN1; SMN2RAB9AKMT2AHSD11B1
SCHEMBL25464172 0.70 SSTR4 (0.44) RAB9ANPC1TAS1R3TAS1R1TAS1R2
SCHEMBL31560752 0.69 LMNA (0.37) TSHRSMN1; SMN2KDM4ETDP1ALDH1A1
SCHEMBL25464147 0.69 PDK1 (0.44) EPHX2SMN1; SMN2RAB9ANPC1TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151074-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151074-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR EPHX2 3721/4885TSHR 123/4885SMN1; SMN2 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback